Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression A recent study in Nature Medicine evaluated the efficacy of prasinezumab, a monoclonal antibody, in slowing the progression of motor symptoms in Parkinson’s disease patients with rapidly progressing forms, using phase II clinical trial data.
https://www.news-medical.net/n....ews/20240419/Monoclo